Full name
A Prospective, Multi-Centre Study (B-Sure) to Evaluate Long-Term Durability of Sustained Virologic Response in Chronic Hepatitis B Participants With and Without Nucleos(t)Ide Therapy Who Have Received and Responded to Bepirovirsen in a Previous Treatment Study
NCT Number
NCT04954859
Geography
US
Non-US
Locations
Argentina, Bulgaria, Canada, China, France, Hong Kong, Italy, Japan, Republic of Korea, Malaysia, Poland, Romania, Russian Federation, Singapore, South Africa, Spain, Thailand, United Kingdom, United States
Primary Endpoints
- Time from achieving SVR in previous Bepirovirsen treatment study to loss of SVR (1st occurrence of either hepatitis B surface antigen or hepatitis B virus deoxyribonucleic acid [DNA] reversion, or 1st use of any rescue medication)-NA naïve participants. From primary endpoint assessment in the previous Bepirovirsen study up to End of Study (Month 33)
- Time from NA cessation to the loss of SVR-NA controlled participants. From Visit 3 (Month 3) up to End of Study (Month 33)
External Link
https://clinicaltrials.gov/study/NCT04954859
Order
1
Disease
Version
Phase
2